Comparison of the Skin Conductance Values and Patient Pain Scores During Minor Procedures in the ICU
Launched by HOPITAL FOCH · Oct 13, 2016
Trial Information
Current as of October 15, 2025
Completed
Keywords
ClinConnect Summary
Although pain must be assessed to be treated, it has been challenging to obtain consistent, objective, and quantifiable measurements. The best methods currently available are subjective scales communicated by the patient such as standardized sentences, visual analog scales (VAS), or plain numeric scales. When a patient is unable to communicate, methods used to monitor pain are inadequate. A device that provides an objective assessment of pain in these patients would alert the patient's caregivers that the patient may be in pain and analgesic treatment is indicated.
Various methods (Evans e...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients between the ages of 18-89 years (inclusive), in an adult ICU
- • Patients admitted to the ICU who are able to communicate their pain and anxiety using a VAS
- • Patients must be cooperative and not agitated.
- • Planned to have a potentially painful procedure
- Exclusion Criteria:
- • Diagnosed neuropathic disease
- • Use of neostigmine within the past 3 hours
- • Use of regional anesthesia at the extremity where the device electrodes are placed -
About Hopital Foch
Hospital Foch is a leading healthcare institution located in Suresnes, France, renowned for its commitment to innovative medical research and patient-centered care. As a prominent clinical trial sponsor, Hospital Foch actively engages in the development of new therapeutic approaches across various medical disciplines, facilitating cutting-edge studies that aim to enhance treatment outcomes and improve patient quality of life. With a multidisciplinary team of experienced researchers and healthcare professionals, the hospital fosters a collaborative environment that prioritizes ethical standards and scientific rigor, ensuring the highest quality in clinical trial execution and patient safety.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Suresnes, France
Suresnes, France
Patients applied
Trial Officials
Marc Fischler, MD, PhD
Principal Investigator
Hôpital Foch
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials